Global site navigation

Global Fund secures deal to slash HIV treatment price
Business and Economy

Global Fund secures deal to slash HIV treatment price

by  AFP 2 min read
The WHO has recommended TLD as the preferred first-line HIV treatment for adults and adolescents as it rapidly suppresses the virus that causes AIDS
The WHO has recommended TLD as the preferred first-line HIV treatment for adults and adolescents as it rapidly suppresses the virus that causes AIDS. Photo: DIPTENDU DUTTA / AFP/File
Source: AFP

PAY ATTENTION: Be the first to follow YEN.com.gh on Threads! Click here!

The Global Fund announced Wednesday a deal with generic pharmaceutical manufacturers to significantly slash the price of a cutting-edge HIV drug, in a move it said would save lives.

The Global Fund, a partnership set up in 2002 to battle AIDS, tuberculosis and malaria, said the agreement would make it possible to provide the advanced pill known as TLD for under $45 per person per year.

"This improved pricing -– a 25-percent reduction -– will allow governments in resource-limited settings to expand access to critical HIV services," it said in a statement.

The three-in-one pill bands together the drugs tenofovir disoproxil fumarate, lamivudine and dolutegravir.

The World Health Organization has recommended it as the preferred first-line HIV treatment for adults and adolescents, since it rapidly suppresses the virus that causes AIDS, has fewer side effects and is easy to take, the statement pointed out.

Read also

US seeking more 'predictable' business environment in China: Raimondo

"The countries most affected by HIV face enormous fiscal constraints, and there are still millions of people who are HIV-positive who don't have access to quality treatment," Global Fund chief Peter Sands said in the statement.

PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app!

"Reduced pricing for TLD means governments and other implementers of Global Fund grants can expand treatment programmes and invest more in prevention, saving more lives and reducing new infections."

Wednesday's announcement comes after the Global Fund, along with UNAIDS, the Bill & Melinda Gates Foundation and other partners in 2017 secured licensing agreements ensuring that TLD could be made available in low- and middle-income countries for up to $75 per person per year -- at the time an unprecedented pricing level.

Thanks to that deal, around 19 million more people living with HIV in resource-constrained settings are today receiving TLD, according to the Clinton Health Access Initiative.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Hot: